Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Equities research analysts at Wedbush upped their Q3 2025 EPS estimates for Fennec Pharmaceuticals in a research report issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of $0.56 for the quarter, up from their previous […]